A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

Background: This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors. Patients and methods: Ninety patients enrolled in this two-part, phase I open-label study of oral brivanib alaninate. The primar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Jonker, D. J., Rosen, L. S., Sawyer, M. B., de Braud, F., Wilding, G., Sweeney, C. J., Jayson, G. C., McArthur, G. A., Rustin, G., Goss, G., Kantor, J., Velasquez, L., Syed, S., Mokliatchouk, O., Feltquate, D. M., Kollia, G., Nuyten, D. S. A., Galbraith, S.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2011
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3139984/
https://ncbi.nlm.nih.gov/pubmed/21131369
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdq599
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge